+关注
白马非马123
暂无个人介绍
IP属地：0
41
关注
0
粉丝
2
主题
0
勋章
主贴
热门
白马非马123
10-07
说说你对这篇新闻的看法...
科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新
白马非马123
08-14
个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！
白马非马123
07-10
$莱斯康制药(LXRX)$
白马非马123
2024-11-26
说说你对这篇新闻的看法...
异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4090542194956520","uuid":"4090542194956520","gmtCreate":1627439295441,"gmtModify":1744048510722,"name":"白马非马123","pinyin":"bmfm123baimafeima123","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":41,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.16","exceedPercentage":"60.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.16","exceedPercentage":"60.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":15,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":486656056606880,"gmtCreate":1759841228830,"gmtModify":1759842992916,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/486656056606880","repostId":"2573644155","repostType":2,"repost":{"id":"2573644155","kind":"news","pubTimestamp":1759709021,"share":"https://www.laohu8.com/m/news/2573644155?lang=&edition=full","pubTime":"2025-10-06 08:03","market":"fut","language":"zh","title":"科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2573644155","media":"智通财经","summary":"智通财经APP讯，科济药业-B 发布公告，将于第67届美国血液学会年会上展示 CT0596的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus平台开发，目前正在复发╱难治性多发性骨髓瘤或浆细胞白血病中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。公司预估2025年下半年提交该品种的IND申请。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。</p><p>CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞白血病(PCL)中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。除了 R/R MM，公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。公司预估2025年下半年提交该品种的IND申请。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-06 08:03 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1352292.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，科济药业-B(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352292.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1574":"生物医药B类股","BK4109":"特种化学制品","02171":"科济药业-B","BK1587":"次新股","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK1161":"生物科技","ASH":"Ashland","BK1585":"昨日强势股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1352292.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2573644155","content_text":"智通财经APP讯，科济药业-B(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞白血病(PCL)中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。除了 R/R MM，公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。公司预估2025年下半年提交该品种的IND申请。","news_type":1,"symbols_score_info":{"02171":1.5,"ASH":1.5}},"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":467575496753504,"gmtCreate":1755171026158,"gmtModify":1755177249014,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","listText":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","text":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/467575496753504","isVote":1,"tweetType":1,"viewCount":840,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":455141526909024,"gmtCreate":1752155792370,"gmtModify":1752158077024,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LXRX\">$莱斯康制药(LXRX)$</a> ","listText":"<a href=\"https://laohu8.com/S/LXRX\">$莱斯康制药(LXRX)$</a> ","text":"$莱斯康制药(LXRX)$","images":[{"img":"https://static.tigerbbs.com/dc8d0afd9f7942db1749eaee30044afd","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/455141526909024","isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":375160802943256,"gmtCreate":1732634187394,"gmtModify":1732634421276,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375160802943256","repostId":"1178300881","repostType":2,"repost":{"id":"1178300881","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1732611797,"share":"https://www.laohu8.com/m/news/1178300881?lang=&edition=full","pubTime":"2024-11-26 17:03","market":"hk","language":"zh","title":"异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场","url":"https://stock-news.laohu8.com/highlight/detail?id=1178300881","media":"异动解读","summary":"金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:\n\n一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。\n\n二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。","content":"<p>金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:</p>\n\n<p>一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。</p>\n\n<p>二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2024-11-26 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:</p>\n\n<p>一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。</p>\n\n<p>二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KC":"金山云"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178300881","content_text":"金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:\n一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。\n二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。","news_type":1,"symbols_score_info":{"KC":1}},"isVote":1,"tweetType":1,"viewCount":1516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":455141526909024,"gmtCreate":1752155792370,"gmtModify":1752158077024,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LXRX\">$莱斯康制药(LXRX)$</a> ","listText":"<a href=\"https://laohu8.com/S/LXRX\">$莱斯康制药(LXRX)$</a> ","text":"$莱斯康制药(LXRX)$","images":[{"img":"https://static.tigerbbs.com/dc8d0afd9f7942db1749eaee30044afd","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/455141526909024","isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":486656056606880,"gmtCreate":1759841228830,"gmtModify":1759842992916,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/486656056606880","repostId":"2573644155","repostType":2,"repost":{"id":"2573644155","kind":"news","pubTimestamp":1759709021,"share":"https://www.laohu8.com/m/news/2573644155?lang=&edition=full","pubTime":"2025-10-06 08:03","market":"fut","language":"zh","title":"科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2573644155","media":"智通财经","summary":"智通财经APP讯，科济药业-B 发布公告，将于第67届美国血液学会年会上展示 CT0596的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus平台开发，目前正在复发╱难治性多发性骨髓瘤或浆细胞白血病中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。公司预估2025年下半年提交该品种的IND申请。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。</p><p>CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞白血病(PCL)中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。除了 R/R MM，公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。公司预估2025年下半年提交该品种的IND申请。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-06 08:03 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1352292.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，科济药业-B(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352292.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1574":"生物医药B类股","BK4109":"特种化学制品","02171":"科济药业-B","BK1587":"次新股","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK1161":"生物科技","ASH":"Ashland","BK1585":"昨日强势股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1352292.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2573644155","content_text":"智通财经APP讯，科济药业-B(02171)发布公告，将于第67届美国血液学会年会上展示 CT0596(一种靶向BCMA的同种异体CAR-T细胞候选产品)的临床数据。摘要和进一步信息将于美国东部时间2025年11月3日后公布。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在复发╱难治性多发性骨髓瘤(R/R MM)或浆细胞白血病(PCL)中开展研究者发起的临床试验。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号，在所有预设剂量组均观察到CAR-T细胞的扩增。除了 R/R MM，公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。公司预估2025年下半年提交该品种的IND申请。","news_type":1,"symbols_score_info":{"02171":1.5,"ASH":1.5}},"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":467575496753504,"gmtCreate":1755171026158,"gmtModify":1755177249014,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","listText":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","text":"个人不是医药行业人士，单从我个人认知方面思考创新药发展，从开始国内的低端产业慢慢的赶超国际比如最初的鞋服，到后面的手机，到当下的汽车。都是一个从低端制造往高端制造赶超，每一次的赶超都会造就一批知名企业名利双收。我们如果想在股市赚大钱最好的方法就是找到下一个赶超的行业，在众多的行业中我觉得创新药最有潜力，买入安静的持有，静待花开。前途是光明的，道路是曲折的！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/467575496753504","isVote":1,"tweetType":1,"viewCount":840,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":375160802943256,"gmtCreate":1732634187394,"gmtModify":1732634421276,"author":{"id":"4090542194956520","authorId":"4090542194956520","name":"白马非马123","avatar":"https://static.tigerbbs.com/395ddb5d41bef038bf6c31fd6f8636ee","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090542194956520","authorIdStr":"4090542194956520"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375160802943256","repostId":"1178300881","repostType":2,"repost":{"id":"1178300881","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1732611797,"share":"https://www.laohu8.com/m/news/1178300881?lang=&edition=full","pubTime":"2024-11-26 17:03","market":"hk","language":"zh","title":"异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场","url":"https://stock-news.laohu8.com/highlight/detail?id=1178300881","media":"异动解读","summary":"金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:\n\n一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。\n\n二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。","content":"<p>金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:</p>\n\n<p>一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。</p>\n\n<p>二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 金山云盘前大跌9.93% 机构和南向资金高位抛售获利入场\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2024-11-26 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:</p>\n\n<p>一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。</p>\n\n<p>二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KC":"金山云"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178300881","content_text":"金山云(KC)今晨盘前股价大跌9.93%,引发市场广泛关注。导致该股暴跌的主要原因有以下两点:\n一是公司近期遭到基金和南向资金的大肆抛售。数据显示,上周多家机构对金山云进行大举获利了结,尤其在11月22日,南向资金净卖出金额更是高达6465万港元,创下单日卖出额新高。大幅资金外流对股价造成了较大压力。\n二是该股涨幅过大,股价存泡沫成分。数据显示,上月以来该股已累计涨超160%,一度触及高点,因此部分投资者高位获利套现有助于推升本轮下跌。","news_type":1,"symbols_score_info":{"KC":1}},"isVote":1,"tweetType":1,"viewCount":1516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
